Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090327 | 0.90 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4034192 | 0.90 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4034189 | 0.90 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4028931 | 0.88 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4028925 | 0.88 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL5157051 | 0.85 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4026563 | 0.84 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4026567 | 0.84 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4027288 | 0.83 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4027286 | 0.83 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562588-A4 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | claimed |
| EP-1562588-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | claimed |